Norden Group LLC Increases Position in Medpace Holdings, Inc. $MEDP

Norden Group LLC increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 956.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 13,038 shares of the company’s stock after buying an additional 11,804 shares during the period. Medpace comprises about 0.7% of Norden Group LLC’s holdings, making the stock its 24th biggest position. Norden Group LLC’s holdings in Medpace were worth $7,323,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. AQR Capital Management LLC grew its stake in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the period. Norges Bank purchased a new stake in shares of Medpace during the 2nd quarter valued at $66,597,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. Clarkston Capital Partners LLC bought a new stake in shares of Medpace during the 2nd quarter worth $40,569,000. Finally, Bares Capital Management Inc. boosted its holdings in shares of Medpace by 319.2% in the 2nd quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock worth $49,302,000 after buying an additional 119,608 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 20.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Royal Bank Of Canada started coverage on shares of Medpace in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 target price on the stock. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $486.67.

Medpace Stock Performance

MEDP stock opened at $466.60 on Friday. The stock has a fifty day moving average of $497.26 and a 200-day moving average of $537.33. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The company has a market capitalization of $13.24 billion, a price-to-earnings ratio of 30.50, a PEG ratio of 2.24 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.